{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:01:34Z","timestamp":1783105294998,"version":"3.54.6"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0915-4","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T07:30:02Z","timestamp":1527060602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of synthetic adrenocorticotropic hormone in patients with IgA nephropathy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-4821","authenticated-orcid":false,"given":"Bhanu","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C. E.","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"issue":"4","key":"915_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0272-6386(12)70293-7","volume":"20","author":"G D'Amico","year":"1992","unstructured":"D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis. 1992;20(4):315\u201323.","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"915_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"12","key":"915_CR3","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC, Registry TG. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"915_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/ndt\/17.7.1197","volume":"17","author":"JV Donadio","year":"2002","unstructured":"Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002;17(7):1197\u2013203.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"915_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfg207","volume":"18","author":"CC Geddes","year":"2003","unstructured":"Geddes CC, Rauta V, Gronhagen-Riska C, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18(8):1541\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"915_CR6","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694\u2013701.","journal-title":"Nephrol Dial Transplant"},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DDDT.S17521","volume":"5","author":"AS Bomback","year":"2011","unstructured":"Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011;5:147\u201353.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"915_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrneph.2011.190","volume":"8","author":"R Gong","year":"2011","unstructured":"Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2011;8(2):122\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"915_CR9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1681\/ASN.2009101025","volume":"21","author":"A Lindskog","year":"2010","unstructured":"Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21(8):1290\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"915_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"915_CR11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","volume":"29","author":"MA Hladunewich","year":"2014","unstructured":"Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"915_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.kint.2016.04.018","volume":"90","author":"JM Thurman","year":"2016","unstructured":"Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016;90(4):746\u201352.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-0915-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T19:05:20Z","timestamp":1558551920000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0915-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"4 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study (REB-16-122) was approved by the Regina Qu\u2019 Appelle Health Region Research Ethics Board. It was found to be acceptable on ethical grounds for research involving human. Written informed consent was obtained from all participants before commencing the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient prior to the use of their data for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"118"}}